adminVistagen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Conference Call June 17, 2025 5:00 PM ET
Company Participants
Cynthia Lynn Anderson – VP & Chief Financial Officer
Mark Adrian McPartland – Senior Vice President of Investor Relations
Shawn K. Singh – President, CEO & Director
Conference Call Participants
Julian Pino – Stifel, Nicolaus & Company, Incorporated, Research Division
Lin Tsai – Jefferies LLC, Research Division
Myles Robert Minter – William Blair & Company L.L.C., Research Division
Operator
Good day, everyone, and thank you for standing by. Welcome to the Vistagen Therapeutics Fiscal Year-End 2025 Corporate Update Conference Call and Webcast. Please note that today’s call is being recorded.
At this time, I’d like to turn the call over to your host, Mark McPartland, Senior Vice President, Investor Relations at Vistagen. Mark, please go ahead.
Mark Adrian McPartland
Thank you, Victor. Good afternoon, everyone, and welcome to Vistagen’s Fiscal Year-end 2025 Corporate Update Conference Call and Webcast. Earlier this afternoon, we issued a press release for our fiscal year-end 2025, which ended on March 31, 2025, provided an overview of our progress across our lead clinical stage neuroscience programs. We encourage you to review the release and the 10- K, which can be found on our website’s Investors section.
Before we begin, please note that we will make forward-looking statements regarding our business during today’s call based on current expectations and information. These forward-looking statements speak only as of today, except as law requires. We do not assume any duty to update any forward-looking statements made today or in the future.
Of course, forward-looking statements involve risks and uncertainties, and our actual results could differ materially from those anticipated by any forward-looking statements we may make today. Additional information concerning risks and factors that could affect our business and financial results are included in our
Read the full article here
